Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4- IFN-γ+ cells, and decreased macrophage IL-6 expression

International Immunopharmacology

Volumn 9, Issue 1, 2009, Pages 134-143

  Imler Jr , Toby J ^a   Petro, Thomas M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cytokines; EAE; Macrophages; Resveratrol; T cells

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 23P19; INTERLEUKIN 6; RESVERATROL;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; DISEASE SEVERITY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD4; BRAIN; DIET; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; FREUND'S ADJUVANT; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-6; MACROPHAGES; MICE; MONOCYTES; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; STILBENES; T-LYMPHOCYTES;

EID: 58149461554     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.10.015     Document Type: Article

References (79)

1. Rosenberg G.A. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8 6 (2002) 586-595
2. Hafler D.A., and Weiner H.L. T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol Rev 100 (1987) 307-332
3. Pugliatti M., Sotgiu S., and Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104 3 (2002) 182-191
4. Weiner H.L., Hafler D.A., Fallis R.J., Johnson D., Ault K.A., and Hauser S.L. T cell subsets in patients with multiple sclerosis. An overview. Ann N Y Acad Sci 436 (1984) 281-293
5. Rasmussen S., Wang Y., Kivisakk P., Bronson R.T., Meyer M., Imitola J., et al. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing-remitting experimental autoimmune encephalomyelitis. Brain 130 Pt 11 (2007) 2816-2829
6. Calabresi P.A., Fields N.S., Farnon E.C., Frank J.A., Bash C.N., Kawanashi T., et al. ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions. J Neuroimmunol 85 2 (1998) 212-219
7. Schonrock L.M., Gawlowski G., and Brück W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett 294 1 (2000) 45-48
8. Vaknin-Dembinsky A., Balashov K., and Weiner H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 176 12 (2006) 7768-7774
9. Li Y., Chu N., Hu A., Gran B., Rostami A., and Zhang G.-X. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 130 2 (2007) 490-501
10. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5 2 (1999) 101-104
11. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 5 (2002) 500-508
12. Gran B., Zhang G.X., Yu S., Li J., Chen X.H., Ventura E.S., et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 169 12 (2002) 7104-7110
13. Gran B., Zhang G.X., and Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev Immunol 24 2 (2004) 111-128
14. Becher B., Durell B.G., and Noelle R.J. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 112 8 (2003) 1186-1191
15. Samoilova E.B., Horton J.L., Hilliard B., Liu T.-S.T., and Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 161 12 (1998) 6480-6486
16. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177 1 (2006) 566-573
17. Woltman A.M., de Haij S., Boonstra J.G., Gobin S.J., Daha M.R., and van Kooten C. Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol 11 11 (2000) 2044-2055
18. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., et al. Human T(H)17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13 10 (2007) 1173-1175
19. Tsaknaridis L., Spencer L., Culbertson N., Hicks K., LaTocha D., Chou Y.K., et al. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 74 2 (2003) 296-308
20. Yao Z., Fanslow W.C., Seldin M.F., Rousseau A.-M., Painter S.L., Comeau M.R., et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3 6 (1995) 811-821
21. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-{beta} and TNF-{alpha}, by human macrophages. J Immunol 160 7 (1998) 3513-3521
22. Chaudhuri A., Yang B., Gendelman H.E., Persidsky Y., and Kanmogne G.D. STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood 111 4 (2008) 2062-2072
23. Sparkman N.L., Buchanan J.B., Heyen J.R.R., Chen J., Beverly J.L., and Johnson R.W. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci 26 42 (2006) 10709-10716
24. Monje M.L., Toda H., and Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302 5651 (2003) 1760-1765
25. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 7090 (2006) 235-238
26. Rangachari M., Mauermann N., Marty R.R., Dirnhofer S., Kurrer M.O., Komnenovic V., et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 203 8 (2006) 2009-2019
27. Sonderegger I., Rohn T.A., Kurrer M.O., Iezzi G., Zou Y., Kastelein R.A., et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 36 11 (2006) 2849-2856
28. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198 12 (2003) 1951-1957
29. Kim H.R., Cho M.L., Kim K.W., Juhn J.Y., Hwang S.Y., Yoon C.H., et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways. Rheumatol (Oxf) 46 1 (2007) 57-64
30. Bao L., Lindgren J.U., van der Meide P., Zhu S., Ljunggren H.G., and Zhu J. The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol 12 4 (2002) 420-429
31. Chan M.M. Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem Pharmacol 63 2 (2002) 99-104
32. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 7117 (2006) 337-342
33. Rahman I., Biswas S.K., and Kirkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 72 11 (2006) 1439-1452
34. Lee K.W., and Lee H.J. The roles of polyphenols in cancer chemoprevention. Biofactors 26 2 (2006) 105-121
35. Tredici G., Miloso M., Nicolini G., Galbiati S., Cavaletti G., and Bertelli A. Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant?. Drugs Exp Clin Res 25 2-3 (1999) 99-103
36. Yoshida Y., Shioi T., and Izumi T. Resveratrol ameliorates experimental autoimmune myocarditis. Circ J 71 3 (2007) 397-404
37. Elmali N., Esenkaya I., Harma A., Ertem K., Turkoz Y., and Mizrak B. Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm Res 54 4 (2005) 158-162
38. Elmali N., Baysal O., Harma A., Esenkaya I., and Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 30 1-2 (2007) 1-6
39. Ma Z.H., Ma Q.Y., Wang L.C., Sha H.C., Wu S.L., and Zhang M. Effect of resveratrol on peritoneal macrophages in rats with severe acute pancreatitis. Inflamm Res 54 12 (2005) 522-527
40. Shindler K.S., Ventura E., Rex T.S., Elliott P., and Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 48 8 (2007) 3602-3609
41. Zhong M., Cheng G.F., Wang W.J., Guo Y., Zhu X.Y., and Zhang J.T. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 6 2 (1999) 79-84
42. Gao X., Xu Y.X., Janakiraman N., Chapman R.A., and Gautam S.C. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 62 9 (2001) 1299-1308
43. Culpitt S.V., Rogers D.F., Fenwick P.S., Shah P., De Matos C., Russell R.E., et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58 11 (2003) 942-946
44. Singh N.P., Hegde V., Hofseth L.J., Nagarkatti M., and Nagarkatti P. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis (EAE) primarily via induction of apoptosis in T cells involving activation of AhR and ER. Mol Pharmacol 72 6 (2007) 508-521
45. Reeves P.G., Nielsen F.H., and Fahey Jr. G.C. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123 11 (1993) 1939-1951
46. Stromnes I.M., and Goverman J.M. Active induction of experimental allergic encephalomyelitis. Nat Protoc 1 4 (2006) 1810-1819
47. Petro T.M. Disparate expression of IL-12 by SJL/J and B10.S macrophages during Theiler's virus infection is associated with activity of TLR7 and mitogen-activated protein kinases. Microbes Infect 7 2 (2005) 224-232
48. Zamvil S.S., and Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8 (1990) 579-621
49. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., and Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11 3 (2005) 335-339
50. Bernard C.C., and Carnegie P.R. Experimental autoimmune encephalomyelitis in mice: immunologic response to mouse spinal cord and myelin basic proteins. J Immunol 114 5 (1975) 1537-1540
51. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201 2 (2005) 233-240
52. Kroenke M.A., Carlson T.J., Andjelkovic A.V., and Segal B.M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 205 (2008) 1535-1541
53. Weaver C.T., Hatton R.D., Mangan P.R., and Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25 1 (2007) 821-852
54. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8 12 (2007) 1390-1397
55. Chan S.H., Perussia B., Gupta J.W., Kobayashi M., Pospisil M., Young H.A., et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173 4 (1991) 869-879
56. Zhang B.-n., Yamamura T., Kondo T., Fujiwara M., and Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 186 10 (1997) 1677-1687
57. Winkler-Pickett R., Young H.A., Cherry J.M., Diehl J., Wine J., Back T., et al. In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J Immunol 180 7 (2008) 4495-4506
58. Okuda Y., Sakoda S., Fujimura H., Saeki Y., Kishimoto T., and Yanagihara T. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glycoprotein 35-55 induced experimental autoimmune encephalomyelitis. J Neuroimmunol 101 2 (1999) 188-196
59. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., and Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278 3 (2003) 1910-1914
60. Jankovic D., and Trinchieri G. IL-10 or not IL-10: that is the question. Nat Immunol 8 12 (2007) 1281-1283
61. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 8 12 (2007) 1363-1371
62. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., and Van Kaer L. NKT cells: what's in a name?. Nat Rev, Immunol 4 3 (2004) 231-237
63. Singh A.K., Wilson M.T., Hong S., Olivares-Villagomez D., Du C., Stanic A.K., et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 194 12 (2001) 1801-1811
64. Furlan R., Bergami A., Cantarella D., Brambilla E., Taniguchi M., et al. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol 33 7 (2003) 1830-1838
65. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., et al. IL-23 promotes tumour incidence and growth. Nature 442 (2006) 461-465
66. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 6954 (2003) 191-196
67. Araki T., Sasaki Y., and Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305 5686 (2004) 1010-1013
68. Imai S., Armstrong C.M., Kaeberlein M., and Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403 6771 (2000) 795-800
69. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305 5682 (2004) 390-392
70. Pfluger P.T., Herranz D., Velasco-Miguel S., Serrano M., and Tschop M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 105 28 (2008) 9793-9798
71. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J 23 12 (2004) 2369-2380
72. Frescas D., Valenti L., and Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 280 21 (2005) 20589-20595
73. Ulrich S., Loitsch S.M., Rau O., von Knethen A., Brune B., Schubert-Zsilavecz M., et al. Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res 66 14 (2006) 7348-7354
74. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55 8 (2006) 2180-2191
75. Dasgupta B., and Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 104 17 (2007) 7217-7222
76. Jager S., Handschin C., St-Pierre J., and Spiegelman B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 104 29 (2007) 12017-12022
77. Murias M., Handler N., Erker T., Pleban K., Ecker G., Saiko P., et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 12 21 (2004) 5571-5578
78. Leiro J., Alvarez E., Arranz J.A., Laguna R., Uriarte E., and Orallo F. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol 75 6 (2004) 1156-1165
79. Gehm B.D., McAndrews J.M., Chien P.-Y., and Jameson J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. PNAS 94 25 (1997) 14138-14143